Median Progression-Free Survival (PFS)

Median PFS of 16.4 months demonstrated in DESTINY-Breast012

Probability of PFS for patients with HER2+ unresectable or mBC receiving ENHERTU 5.4 mg/kg (N=184)2,a

16.4 month average of progression-free survival in patients receiving ENHERTU 5.4 mg/kg 16.4 month average of progression-free survival in patients receiving ENHERTU 5.4 mg/kg

aOf the 184 patients, 48 had progressive disease and 10 had died by 20 months; data for 126 patients were censored, as indicated by tick marks. Disease progression was assessed using modified RECIST v1.1. Dashed lines indicate the 95% CI. Based upon median duration of follow-up of 11.1 months at data cut-off date of August 1, 2019.2
NR, not reached.

  • In a prespecified exploratory subgroup analysis, median PFS in the 24 patients with inactive brain metastases was 18.1 months (95% CI: 6.7, 18.1)2

Median overall survival was not reached in DESTINY-Breast01 at median
follow-up of 11.1 months, data cutoff August 1, 20192

  • ENHERTU received accelerated approval from FDA based on tumor response rate and duration of response. FDA has not reviewed the PFS and OS data. Multiple confirmatory Phase 3 studies are underway3
Ready to learn more about ENHERTU?